Analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share (EPS) of ($1.48) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.51) to ($1.44). Atara Biotherapeutics posted earnings of ($1.05) per share in the same quarter last year, which suggests a negative year over year growth rate of 41%. The business is expected to announce its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.99) per share for the current financial year, with EPS estimates ranging from ($6.11) to ($5.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($5.70) per share, with EPS estimates ranging from ($6.18) to ($5.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.44).

Several analysts have recently weighed in on ATRA shares. ValuEngine cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 10th. Mizuho started coverage on shares of Atara Biotherapeutics in a research report on Tuesday, January 22nd. They set a “buy” rating and a $62.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, April 1st. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 7th. Finally, Cowen restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. Three analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $49.00.

Shares of Atara Biotherapeutics stock traded up $1.80 on Tuesday, hitting $33.49. 318,363 shares of the company traded hands, compared to its average volume of 459,776. The stock has a market cap of $1.46 billion, a P/E ratio of -6.35 and a beta of 2.25. Atara Biotherapeutics has a 12-month low of $27.85 and a 12-month high of $54.45.

In related news, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction on Thursday, January 24th. The shares were sold at an average price of $35.06, for a total value of $273,468.00. Following the transaction, the chief executive officer now owns 433,111 shares in the company, valued at approximately $15,184,871.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Derrell Porter sold 5,909 shares of Atara Biotherapeutics stock in a transaction on Friday, February 15th. The stock was sold at an average price of $40.00, for a total transaction of $236,360.00. Following the completion of the transaction, the senior vice president now owns 27,597 shares in the company, valued at approximately $1,103,880. The disclosure for this sale can be found here. In the last quarter, insiders sold 162,524 shares of company stock worth $6,069,971. 10.60% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc raised its position in Atara Biotherapeutics by 4.5% in the 3rd quarter. Vanguard Group Inc now owns 2,487,567 shares of the biotechnology company’s stock worth $102,861,000 after purchasing an additional 106,213 shares during the period. Neuberger Berman Group LLC grew its holdings in Atara Biotherapeutics by 6.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,218,539 shares of the biotechnology company’s stock worth $50,386,000 after acquiring an additional 74,833 shares during the last quarter. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics in the 3rd quarter worth $108,000. Dimensional Fund Advisors LP grew its holdings in Atara Biotherapeutics by 1,801.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 229,141 shares of the biotechnology company’s stock worth $9,474,000 after acquiring an additional 217,088 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Atara Biotherapeutics by 12.7% in the 3rd quarter. AQR Capital Management LLC now owns 21,609 shares of the biotechnology company’s stock worth $894,000 after acquiring an additional 2,439 shares during the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.